Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Buecher

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
The Lancet. Oncology|July 26, 2018
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 studyStefano Kim, Eric François, Thierry André, et al.
European Journal of Human Genetics : EJHG|January 21, 2016
Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS studyAmandine I Garcia, Monique Buisson, Francesca Damiola, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2015
Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 CarriersJulie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Therapeutic Advances in Medical Oncology|December 17, 2020
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinomaStefano Kim, Aurélia Meurisse, Laurie Spehner, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
Carcinogenesis|October 6, 2017
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia familiesAnne-Laure Renault, Noura Mebirouk, Eve Cavaciuti, et al.
JAMA Ophthalmology|June 18, 2025
Uveal Melanoma and the Lynch Syndrome Tumor SpectrumAnaïs Le Ven, Marie-Charlotte Villy, André Bortolini Silveira, et al.
Journal of Medical Genetics|August 29, 2022
First estimates of diffuse gastric cancer risks for carriers of <i>CTNNA1</i> germline pathogenic variantsMarie Coudert, Youenn Drouet, Hélène Delhomelle, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2026
Cancer risks for ATM variant heterozygotesYue Jiao, David E Goldgar, Dorothée Le Gal, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|July 26, 2018
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 studyStefano Kim, Eric François, Thierry André, et al.
European Journal of Human Genetics : EJHG|January 21, 2016
Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS studyAmandine I Garcia, Monique Buisson, Francesca Damiola, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 24, 2015
Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 CarriersJulie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, et al.
Therapeutic Advances in Medical Oncology|December 17, 2020
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinomaStefano Kim, Aurélia Meurisse, Laurie Spehner, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
Carcinogenesis|October 6, 2017
Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia familiesAnne-Laure Renault, Noura Mebirouk, Eve Cavaciuti, et al.
JAMA Ophthalmology|June 18, 2025
Uveal Melanoma and the Lynch Syndrome Tumor SpectrumAnaïs Le Ven, Marie-Charlotte Villy, André Bortolini Silveira, et al.
Journal of Medical Genetics|August 29, 2022
First estimates of diffuse gastric cancer risks for carriers of <i>CTNNA1</i> germline pathogenic variantsMarie Coudert, Youenn Drouet, Hélène Delhomelle, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 29, 2026
Cancer risks for ATM variant heterozygotesYue Jiao, David E Goldgar, Dorothée Le Gal, et al.
Pageof 12